MannKind Corporation logo
MannKind Corporation MNKD
$ 3.34 1.52%
report update icon

Quarterly report 2026-Q2
added 08-05-2026

MannKind Corporation Cash Flow 2025-1992 | MNKD

Brief overview of MannKind Corporation's cash movements

The comparison covers five available annual reports between 2021 and 2025.

Operating cash flow recovered from negative territory and reached $18.3 million. Core operations returned to generating cash.

3 of the five observations were positive. The cash profile is workable, though volatile.

At the end, 5.2% of revenue converted into operating cash flow versus -81.8% previously.

Estimated working capital increased by $59.7 million, equal to 17.1% of latest revenue. More cash became tied up in receivables and inventory.

What the cash flows show

MannKind Corporation's cash generation remains workable and supports the business, though some uses of cash limit flexibility.

Annual Cash Flow MannKind Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992

Operating Cash Flow

18.3 M 42.5 M 34.1 M -80.7 M -61.7 M -28.1 M -88.5 M -37.7 M -64.8 M -78.1 M - - -129 M -120 M -124 M -149 M -184 M - - - - - - - - - - - - - - - - -

Depreciation & Amortization

12.3 M 7.37 M 4.54 M 3.32 M 1.99 M 2.15 M 972 K 2.86 M 1.8 M 2.4 M 11 M 9.8 M 11.5 M 13 M 14.6 M 16.5 M 18.7 M - - - - - - - - - - - - - - - - -

Accounts Payables

9.03 M 6.79 M 9.58 M 11.1 M 6.96 M 5.58 M 4.79 M 5.38 M 6.98 M 3.26 M 15.6 M 7.39 M 3.86 M 4.56 M 4.62 M 3.29 M - - - - - - - - - - - - - - - - - -

Accounts Receivables

38.4 M 11.8 M 14.9 M 16.8 M 4.74 M 4.22 M 3.51 M 4.02 M 2.79 M 302 K 23 K 50.4 M - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

35.3 M 27.9 M 28.5 M 21.8 M 7.15 M 4.97 M 4.16 M 3.6 M 2.66 M 2.33 M - 9.67 M - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow MannKind Corporation

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-23.7 M -5.36 M - - -6.38 M - - - 6.7 M - - - 1.16 M - -78.3 M -50.2 M -18.2 M - -49.4 M -34.2 M -12.7 M - -28.4 M -14.9 M -11.2 M - -83.4 M -31.3 M -11.6 M - -62.7 M -48.8 M -21.6 M - -34.8 M -11.5 M - - - - - - - - - - - - - - - - -32 M - -91.8 M -57.5 M -32.5 M - -103 M -67.4 M -30.7 M

Depreciation & Amortization

12.8 M 6.38 M 2.01 M 2.04 M 2.11 M - 2.1 M 1.71 M 1.36 M - 1.12 M 1.1 M 1.06 M - 952 K 727 K 599 K - 3 M 1.67 M 655 K - 1.64 M 1.1 M 538 K - 407 K 739 K 367 K - 2.49 M 1.46 M 706 K - 2.71 M 1.79 M 400 K - 3.1 M 589 K 600 K - 3.16 M 2.74 M 2.3 M - 2.45 M 2.45 M 2.5 M - 2.87 M 2.96 M 2.99 M - 3.24 M 3.3 M 3.36 M - 3.74 M 3.58 M 4.12 M

Accounts Payables

11 M 16.1 M 7.27 M 10.3 M 5.04 M 6.79 M 6.44 M 9.56 M 7.15 M 9.58 M 16.8 M 17.1 M 13.9 M 11.1 M 9.87 M 7.82 M 8.7 M 6.96 M 9.53 M 7.49 M 6.71 M 5.58 M 5.58 M 5.58 M 5.58 M 4.79 M 4.79 M 4.79 M 4.79 M 5.38 M 5.38 M 5.38 M 5.38 M 6.98 M 6.98 M 6.98 M 6.98 M 3.26 M 3.26 M 3.26 M 3.26 M 15.6 M 15.6 M 15.6 M 15.6 M 7.39 M 7.39 M 7.39 M 7.39 M 3.86 M 3.86 M 3.86 M 3.86 M 4.56 M 4.56 M 4.56 M 4.56 M 4.62 M 4.62 M 4.62 M 4.62 M

Accounts Receivables

43.2 M 28.1 M 17.4 M 27.1 M 28.9 M 11.8 M 18.2 M 23.3 M 19.9 M 14.9 M 21.8 M 27.8 M 19.7 M 16.8 M 23.5 M 15 M 9.82 M 4.74 M 9.44 M 6.3 M 3.57 M 4.22 M 4.22 M 4.22 M 4.22 M 3.51 M 3.51 M 3.51 M 3.51 M 4.02 M 4.02 M 4.02 M 4.02 M 2.79 M 2.79 M 2.79 M 2.79 M 302 K 302 K 302 K 302 K 23 K 1.68 M 23 K 23 K 50.4 M 50.4 M 50.4 M 50.4 M - - - - - - - - - - - -

Total Inventories

44.4 M 49.2 M 27 M 28.5 M 28.9 M 27.9 M 26.7 M 24.8 M 26.4 M 28.5 M 27.1 M 25.3 M 22 M 21.8 M 18.3 M 20.6 M 8.04 M 7.15 M 7.48 M 7.48 M 5.05 M 4.97 M 4.97 M 4.97 M 4.97 M 4.16 M 4.16 M 4.16 M 4.16 M 3.6 M 3.6 M 3.6 M 3.6 M 2.66 M 2.66 M 2.66 M 2.66 M 2.33 M 2.33 M 2.33 M 2.33 M - 23.4 M 19.8 M 16.8 M 9.67 M 9.67 M 9.67 M 9.67 M - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company MannKind Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
AnaptysBio AnaptysBio
ANAB
$ 51.0 1.83 % $ 1.48 B usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.88 0.53 % $ 107 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 60.26 0.06 % $ 11.6 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 98.52 0.24 % $ 23.8 B germanyGermany
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.17 0.46 % $ 3.57 M israelIsrael
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 13.99 0.84 % $ 1.25 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.98 0.3 % $ 247 M usaUSA
Codexis Codexis
CDXS
$ 1.32 1.09 % $ 115 M usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
Cerus Corporation Cerus Corporation
CERS
$ 2.62 0.38 % $ 499 M usaUSA
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.13 0.43 % $ 132 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.1 1.16 % $ 2.07 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.25 3.16 % $ 51.9 M israelIsrael
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.8 0.72 % $ 4.69 M usaUSA
AbbVie AbbVie
ABBV
$ 264.34 0.09 % $ 468 B usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.17 1.74 % $ 13.2 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.7 0.4 % $ 3.79 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.4 2.65 % $ 286 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 22.53 0.2 % $ 713 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 116.1 4.93 % $ 12.1 B usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.24 0.74 % $ 82.9 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 7.14 0.19 % $ 95.1 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Curis Curis
CRIS
$ 0.83 1.1 % $ 10.9 M usaUSA
CorMedix CorMedix
CRMD
$ 7.85 1.03 % $ 565 K usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 54.23 0.23 % $ 4.88 B schweizSchweiz
Champions Oncology Champions Oncology
CSBR
$ 4.9 0.1 % $ 67.8 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 11.62 8.21 % $ 918 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 31.41 1.45 % $ 2.98 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.67 2.38 % $ 13.4 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.85 0.2 % $ 929 M canadaCanada
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 64.66 0.17 % $ 7.77 M usaUSA
Daré Bioscience Daré Bioscience
DARE
$ 0.78 4.73 % $ 8.72 M usaUSA
Adagene Adagene
ADAG
$ 2.93 2.86 % $ 173 M chinaChina
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 7.94 1.4 % $ 373 M usaUSA